Capsa Healthcare (“Capsa”), a portfolio company of Levine Leichtman Capital Partners (“LLCP”), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, “RoboPharma”). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe.
Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, enhance medication security, and tighten inventory control across healthcare settings worldwide. Capsa’s core offerings include mobile workstations, medication management solutions, and pharmacy automation products sold to over 3,000 end customers, including leading health systems, senior care communities, and major retail and institutional pharmacies. Capsa was founded in 1958 and is headquartered in Portland, Oregon with additional production facilities in Columbus, Ohio and Agua Prieta, Mexico.
Frank van der Vaart, owner and CEO of RoboPharma, commented, “In Capsa and LLCP, we’ve found both the partner and financial sponsor to help us take RoboPharma to the next level. We’re excited about what this combination can create, as Capsa offers RoboPharma strategic support to accelerate our growth plans in Europe and the United States.”
Avi Zisman, CEO of Capsa, added, “RoboPharma’s market leading products, people, and reputation make it a perfect addition to the Capsa platform. This partnership extends Capsa’s pharmacy automation product portfolio, enhances our engineering and support capabilities, and expands our geographic presence in Europe.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Andrew Schwartz, a Partner at LLCP, stated, “We are excited to demonstrate our continued support of Capsa through this acquisition. RoboPharma strengthens Capsa’s ability to provide highly-valued, comprehensive pharmacy automation solutions to its clients across the globe.”
Capsa is a portfolio company of Levine Leichtman Capital Partners Fund VI, L.P.
Source: Biospace
